Data as of 3:59pm ET
| +0.05 / +1.07%|
Lpath, Inc. operates as a biotechnology company that focuses on the discovery and development of lipidomic-based therapeutic antibodies, an emerging field of medical science that targets bioactive signaling lipids to treat a wide range of human diseases. The company's product candidate, iSONEP, is currently in a Phase 2 clinical trial to assess the efficacy of iSONEP, given alone or in combination with Lucentis, Avastin, or Eylea in subjects with wet AMD, an ocular disease that often leads to blindness. Its second product candidate, ASONEP, is a monoclonal antibody against sphingosine-1-phosphate that has completed a phase 1 clinical trial in cancer patients. The company's third product candidate, Lpathomab is a monoclonal antibody against lysophosphatidic acid, a key bioactive lipid that has been recognized to be involved in diseases of the central nervous system, fibrosis, ocular disease and cancer. Lpath was founded by Roger Allen Sabbadini in September 1997 and is headquartered in San Diego, CA.
|Scott R. Pancoast||President, Chief Executive Officer & Director|
|Gary J. G. Atkinson||Chief Financial Officer, Secretary & Senior VP|
|Gary Woodnutt||Senior Vice President-Research|
|Dario A. Paggiarino||Chief Development Officer & Senior Vice President|
|Roger Allen Sabbadini||Vice President|